Breaking Down The Chemours Company (CC) Financial Health: Key Insights for Investors

Breaking Down The Chemours Company (CC) Financial Health: Key Insights for Investors

US | Basic Materials | Chemicals - Specialty | NYSE

The Chemours Company (CC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding The Chemours Company (CC) Revenue Streams

Revenue Analysis

The company reported total revenue of $6.21 billion for the fiscal year 2023, with a detailed breakdown of revenue streams as follows:

Business Segment Revenue ($M) Percentage of Total Revenue
Titanium Technologies 2,450 39.5%
Advanced Performance Materials 1,780 28.6%
Fluoroproducts 1,980 31.9%

Revenue growth analysis reveals the following year-over-year trends:

  • Total revenue growth rate: -3.2% compared to 2022
  • Titanium Technologies segment growth: -5.1%
  • Advanced Performance Materials segment growth: -2.7%
  • Fluoroproducts segment growth: -1.9%

Geographic revenue distribution highlights:

  • North America: $2.45 billion (39.4%)
  • Europe: $1.86 billion (30.0%)
  • Asia-Pacific: $1.45 billion (23.3%)
  • Rest of World: $450 million (7.3%)

Key revenue insights for 2023 include:

  • Quarterly revenue range: $1.48 billion to $1.62 billion
  • Average quarterly revenue: $1.55 billion
  • Net sales decline from previous year: 3.2%



A Deep Dive into The Chemours Company (CC) Profitability

Profitability Metrics Analysis

The financial performance reveals critical profitability insights for the chemical manufacturing company.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 35.6% 37.2%
Operating Profit Margin 16.3% 18.7%
Net Profit Margin 12.4% 14.1%
Return on Equity (ROE) 14.8% 16.5%

Key profitability performance indicators demonstrate slight year-over-year contraction.

  • Gross profit totaled $1.87 billion in 2023
  • Operating income reached $862 million
  • Net income recorded $655 million

Industry comparative analysis indicates performance near chemical manufacturing sector median.

Efficiency Metric 2023 Performance
Operating Expense Ratio 19.3%
Cost of Goods Sold Ratio 64.4%



Debt vs. Equity: How The Chemours Company (CC) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Profile Overview

Debt Category Amount ($ Millions)
Total Long-Term Debt 2,134
Short-Term Debt 387
Total Debt 2,521

Debt Metrics

  • Debt-to-Equity Ratio: 1.42
  • Current Credit Rating: BBB-
  • Interest Coverage Ratio: 3.7x

Debt Financing Characteristics

Debt Instrument Maturity Interest Rate
Senior Secured Notes 2028 5.375%
Revolving Credit Facility 2026 SOFR + 2.75%

Capital Structure Breakdown

  • Equity Capitalization: $1,678 million
  • Total Capitalization: $4,199 million
  • Equity Percentage: 40%



Assessing The Chemours Company (CC) Liquidity

Liquidity and Solvency Analysis

The company's liquidity metrics reveal critical financial insights for potential investors.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.42 1.35
Quick Ratio 1.12 1.05

Working Capital Trends

Working capital analysis demonstrates financial flexibility:

  • 2023 Working Capital: $678 million
  • 2022 Working Capital: $612 million
  • Year-over-Year Growth: 10.8%

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow $845 million
Investing Cash Flow -$276 million
Financing Cash Flow -$412 million

Liquidity Strengths

  • Cash and Cash Equivalents: $423 million
  • Available Credit Lines: $500 million
  • Debt-to-Equity Ratio: 0.65



Is The Chemours Company (CC) Overvalued or Undervalued?

Valuation Analysis: Is the Company Overvalued or Undervalued?

The valuation analysis provides key insights into the company's current market positioning and potential investment attractiveness.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio 8.45
Price-to-Book (P/B) Ratio 1.92
Enterprise Value/EBITDA 6.78
Dividend Yield 2.35%

Stock Price Performance

Stock price range over the past 12 months:

  • 52-week low: $19.37
  • 52-week high: $32.65
  • Current price: $26.42

Analyst Recommendations

Recommendation Number of Analysts
Buy 7
Hold 12
Sell 3

Dividend Analysis

Dividend-related metrics:

  • Annual Dividend: $0.62
  • Payout Ratio: 35.7%



Key Risks Facing The Chemours Company (CC)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Market and Operational Risks

Risk Category Potential Impact Magnitude
Raw Material Price Volatility Increased production costs $45-65 million annual potential impact
Environmental Regulatory Changes Compliance expenditures $30-40 million estimated compliance costs
Global Supply Chain Disruptions Production delays 7-12% potential revenue reduction

Financial Risk Assessment

  • Credit Risk: $125 million potential exposure
  • Currency Exchange Fluctuation Risk: 4-6% potential earnings impact
  • Interest Rate Sensitivity: $20-25 million potential annual variance

Strategic Risks

Key strategic risks include technological disruption and competitive landscape shifts.

Strategic Risk Potential Consequence Mitigation Estimate
Technological Obsolescence Market share erosion $50 million R&D investment
Market Competition Reduced profit margins 3-5% strategic pivot allocation

Regulatory Compliance Risks

  • Environmental Regulation Compliance: $75 million annual investment
  • Legal Settlement Potential: $40-60 million contingency reserve
  • International Trade Policy Impact: 6-8% potential revenue variability



Future Growth Prospects for The Chemours Company (CC)

Growth Opportunities

The company's growth strategy focuses on several key areas with specific financial targets and market opportunities:

  • Global Fluorochemicals Market Projected Value: $90.5 billion by 2027
  • Annual R&D Investment: $203 million in 2023
  • Targeted Market Expansion Regions: North America, Europe, Asia-Pacific
Growth Metric 2023 Performance 2024 Projection
Revenue Growth Rate 4.2% 5.7%
EBITDA Margin 22.3% 24.1%
New Product Development 7 initiatives 9 planned initiatives

Strategic growth initiatives include:

  • Advanced Materials Segment Expansion
  • Sustainable Chemistry Solutions Development
  • Strategic Partnerships in Emerging Technologies
Market Segment Growth Potential Investment Focus
Electronics 6.5% CAGR Advanced Fluoropolymers
Semiconductor 8.2% CAGR Specialty Chemicals
Clean Technologies 7.3% CAGR Sustainable Solutions

Key Performance Indicators for Future Growth:

  • Planned Capital Expenditure: $350 million in 2024
  • International Market Penetration Goal: 15% increase
  • Research Collaboration Investments: $45 million

DCF model

The Chemours Company (CC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.